144,123 members

Skip to content. | Skip to navigation

News

NICE recommends combination treatment for some lymphoma patients

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

NICE recommends combination treatment for some lymphoma patients

Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.

In new draft guidance, polatuzumab vedotin (also called Polivy and made by Roche) with rituximab and bendamustine has been recommended as a treatment option for adults with diffuse large B-cell lymphoma (DLBCL). The combination treatment will be available from today for patients whose cancer has relapsed or not responded to primary treatment, and who cannot have a haematopoietic stem cell transplant.